Omeros' knee surgery drug fails in late-stage study
(Reuters) - Omeros Corp (OMER.O) said a late-stage trial of its experimental drug for patients undergoing knee surgery did not meet its main goal, sending the company's shares down as much as 10 percent in extended trade.
The company said the drug -- codenamed OMS103HP -- did not meet a patient-reported measure that comprised questions about knee swelling and stiffness.
A second late-stage trial on the drug remains on track and will begin in the first half of 2013, said the company that focuses on treating inflammation and disorders of the central nervous system.
Omeros's shares were down 6 percent at $5.50 after the bell on Thursday. (Reporting by Prateek Kumar; Editing by Sreejiraj Eluvangal)
- Search for Malaysian plane may extend to Indian Ocean - U.S |
- Russia holds war games near Ukraine; Merkel warns of catastrophe |
- New York City gas explosion subject of federal probe |
- UPDATE 1-U.S. investigators suspect missing Malaysian plane flew for hours -WSJ
- White House tried to mediate dispute between Senate, CIA panel: source